Source comparison
BPC-157 and GHK-Cu: Research vs Clinical Comparison
BPC-157 VEGF upregulation, angiogenesis, endothelial migration 200–500 mcg/injection Morning (aligns with growth hormone peak) No human Phase III trials; gastric origin limits systemic bioavailability Animal studies + case reports GHK-Cu Collagen gene transcri
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis, endothelial migration
- 200–500 mcg/injection
- Morning (aligns with growth hormone peak)
- No human Phase III trials; gastric origin limits systemic bioavailability
- Animal studies + case reports
- GHK-Cu
- Collagen gene transcription, lysyl oxidase activation, TGF-β modulation
- 1–3 mg/injection
- Evening (6–8 hours post-BPC-157)
- Copper toxicity above 5 mg/dose; oxidation-sensitive storage
- In vitro + small-scale human dermatology studies
- Combined Protocol
- Dual-pathway activation (vascular + matrix)
- BPC-157 250 mcg AM + GHK-Cu 2 mg PM
- Sequential dosing (8-hour gap)
- No controlled studies on combination therapy; individual response variability
- Observational reports only